Clinical trials: Partial Seizures
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00698581
- Testing
- Brivaracetam
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 88 people
- Sponsor
- UCB Pharma
Epilepsy, Focal Seizures, Partial Seizures
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy.
- Trial name
- OPUS (NCT03283371)
- Testing
- Natalizumab
- Where
- 31 sites in United States
- Volunteers
- 67 people
- Sponsor
- Biogen
Epilepsy
Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures
This is a randomized, double-blind, placebo-controlled, parallel group study to determine the maximum tolerated dose of E2007. Epilepsy patients with refractory partial seizures will be divided into two groups of 24 patients…
- Trial name
- NCT00416195
- Testing
- E2007
- Where
- 2 sites in Latvia
- Volunteers
- 48 people
- Sponsor
- Eisai Co., Ltd.
Partial Epilepsy
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures.
- Trial name
- NCT02535091
- Testing
- YKP3089
- Where
- 121 sites in United States, Argentina and 15 more
- Volunteers
- 1,345 people
- Sponsor
- SK Life Science, Inc.
Partial Seizures, Epilepsies, Partial
Once-A-Day Pregabalin For Partial Seizures
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs.
- Trial name
- NCT01262677
- Testing
- pregabalin
- Where
- 82 sites in United States, Argentina and 16 more
- Volunteers
- 325 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy, Monotherapy
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs)…
- Trial name
- NCT01465997
- Testing
- Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
- Where
- 150 sites in United States, Australia and 27 more
- Volunteers
- 551 people
- Sponsor
- UCB BIOSCIENCES GmbH
Epilepsies, Partial
A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures
This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed N01020 [NCT00160165] or N01221 [NCT00280696].
- Trial name
- NCT00367432
- Testing
- Levetiracetam
- Where
- 53 sites in Japan
- Volunteers
- 398 people
- Sponsor
- UCB Japan Co. Ltd.
Partial Epilepsies
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects…
- Trial name
- NCT00955357
- Testing
- Lacosamide
- Where
- 109 sites in United States, Austria and 13 more
- Volunteers
- 461 people
- Sponsor
- UCB Pharma
Epilepsy
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic…
- Trial name
- ALEX-MT (NCT00520741)
- Testing
- Lacosamide
- Where
- 158 sites in United States, Australia and 11 more
- Volunteers
- 426 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Refractory Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures
This was a phase III 4-part study in multiple centres. Part I was a 26-week parallel-group, randomised, placebo-controlled period (8 weeks single-blind placebo baseline, 2 weeks double-blind titration, 12 weeks maintenance, and 4…
- Trial name
- NCT00957684
- Testing
- eslicarbazepine acetate
- Where
- Portugal
- Volunteers
- 402 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Eslicarbazepine Acetate Monotherapy Long Term Study
This is a long term, open-label, safety extension study in subjects with partial onset seizures.
- Trial name
- NCT00910247
- Testing
- Eslicarbazepine acetate
- Where
- 122 sites in United States, Bulgaria and 4 more
- Volunteers
- 274 people
- Sponsor
- Sumitomo Pharma America, Inc.
Complex Partial Seizures
Intra Cranial EEG Activity During Dexmedetomidine Sedation
Various parts of the brain are sensitive to various anesthetics.We like to study the effect of dexmedetomidine on the different parts of the brain in patients who are coming for DBS electrode removal under sedation.
- Trial name
- NCT01648959
- Testing
- EEG Recording
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- University Health Network, Toronto
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a…
- Trial name
- NCT00957372
- Testing
- eslicarbazepine acetate, ESL - Open-label Extension (Part II)
- Where
- Portugal
- Volunteers
- 253 people
- Sponsor
- Bial - Portela C S.A.
Partial Seizures With or Without Secondary Generalization, Epilepsy
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization…
- Trial name
- NCT03083665
- Testing
- Brivaracetam
- Where
- 94 sites in China, Japan and 5 more
- Volunteers
- 449 people
- Sponsor
- UCB Biopharma SRL
Epilepsies, Partial
A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
Examine the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
- Trial name
- NCT00603473
- Testing
- gabapentin
- Where
- 26 sites in Japan
- Volunteers
- 92 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
The purpose of this study is to evaluate the long-term safety and tolerability of retigabine/ezogabine as an adjunctive treatment in subjects with either partial onset seizures (12 to < 18 years old) or Lennox-Gastaut Syndrome…
- Trial name
- NCT01668654
- Testing
- retigabine/ezogabine
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Partial-onset Seizures
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures
- Trial name
- NCT01618695
- Testing
- Perampanel
- Where
- 117 sites in Australia, China and 5 more
- Volunteers
- 940 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures
The purpose of this study was to evaluate the safety and pharmacokinetics of LCM syrup in children ages from 1 month to 17 years with uncontrolled partial seizures when added to 1 to 3 other antiepileptic drugs (AEDs).
- Trial name
- NCT00938431
- Testing
- Lacosamide
- Where
- 21 sites in United States, Belgium and 1 more
- Volunteers
- 47 people
- Sponsor
- UCB Pharma
Epilepsy, Partial
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
- Trial name
- NCT00160654
- Testing
- Levetiracetam
- Where
- 29 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 251 people
- Sponsor
- UCB Pharma
Epilepsy, Partial
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains…
- Trial name
- VICTOR (NCT01375374)
- Testing
- Lacosamide, Levetiracetam
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 11 people
- Sponsor
- UCB Pharma